ArticleBMC infectious diseases2026
Characteristics of solid versus hematologic malignancies in people living with human immunodeficiency virus.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePeople living with HIV (PLWH) face increased risks of both AIDS-defining and non-AIDS-defining malignancies. We characterized the age-standardized cancer burden, compared clinical characteristics and survival outcomes between hematologic and solid malignancies in PLWH, and performed a secondary analysis stratifying malignancies by viral oncogenesis.
methodsWe conducted a retrospective cohort study of 166 PLWH diagnosed with cancer at a 407-bed tertiary academic medical center in the southern United States between 2019 and 2025. Age-standardized cancer rates proportions were calculated using the direct standardization method with the US 2000 Standard Population as the reference. Demographic, HIV-related, and clinical variables were compared between hematologic and solid malignancies using univariate and multivariate logistic regression. Cox proportional hazards regression and restricted mean survival time analysis were performed to identify predictors of overall survival. The analysis was repeated for virus-driven versus non-virus-driven malignancies.
resultsAmong 3,640 HIV-positive patients actively receiving care at our institution, 166 (4.6%) were identified as having both HIV infection and a concurrent malignancy. The age-standardized cancer detection proportion was 888.1 per 100,000 patients (95% CI 753.0-1023.2). Hematologic malignancies occurred at a younger age than solid tumors (median 41 vs. 51 years, p = 0.002) and were associated with higher HIV viral loads, lower CD4 + counts, and poorer antiretroviral therapy adherence. High HIV viral load remained independently associated with hematologic malignancy in multivariate analysis (OR 4.839, 95% CI 1.495-17.58). Kaplan-Meier analysis demonstrated a trend toward lower overall survival among hematologic malignancy patients compared with solid tumor patients (log-rank p = 0.056), which reached significance after age adjustment in multivariate Cox proportional hazards regression (HR 3.00, 95% CI 1.35-6.66, p = 0.007). In the virus-driven analysis, both high HIV viral load and low CD4 + T-cell count were independently associated with virus-driven malignancy, with CD4 + T-cell count demonstrating a particularly strong association (OR 5.129, 95% CI 1.709-17.153, p = 0.005).
conclusionImmune dysfunction remains strongly associated with hematologic malignancies in PLWH, whereas solid tumors are increasingly associated with age- and lifestyle-related factors. A secondary analysis stratifying malignancies by viral oncogenesis identified consistent associations between immune dysfunction and virus-driven malignancy, further supporting the role of impaired immune surveillance in HIV-associated cancer development. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.